Abstracts

Rationale: The purpose of this study was to evaluate the effects of perampanel (PER) on daytime somnolence and sleep quality in adult patients with focal onset epilepsyMethods: Multicenter prospective study performed during 9 months, assessing daytime somnolence by means of the Epworth Sleepiness Scales (ESS) and sleep quality using the Pittsburgh Sleep Quality Index (PSQI) when available, before starting PER, 3 months and 6 months later. Demographic and clinical data were considered to analyze the resultsResults: We included 73 patients at baseline visit (Age 43, range 17-75 years; 60% Female).Baseline seizure frequency was 46 per month [1-341] PER was used as ≥3rd concomitant AED in all patients. Average baseline ESS (5.78) score was within normal limits and PSQI (7.4) was considered abnormal in the sample. At 3 months follow-up 52 patients received ESS and 35 PSQI. Responder rate (>50%) was 28%. PER median dose 4 mg. Retention rate 73% At 6 moths follow-up 26 patients completed both assessments. Responder rate (>50%) was 46%. PER median dose 6 mg. Retention rate 71%. Overall, drug withdrawn was due to lack of efficacy (12%) or side effects (15%). Most common treatment emergent adverse events were somnolence (21%) and dizziness (16%). Withdrawn was more likely due to adverse events during the first months of treatment, and due to lack of efficacy after that time. At follow-up, daytime sleepiness was not impaired by PER treatment (ESS=6). However, the quality of sleep improved significantly by 2 points in the PSQI (p=0.004). Sleep improvement was sustained at 6 months and independent from demographic variables, seizure response and PER doses. (Table)Conclusions: PER is an effective and safe antiepileptic drug, which can have a sustained effect over the quality of sleep without impact in the daytime somnolence.